Investor Update
Basel, 10 September 2007
R7128
Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
Pharmasset
Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
Dear
Investor,
Please find attached two Pharmasset news releases sent
out today.
Please do not hesitate to contact us if you have any further
questions.